Correction to: Hypertension Research (2013) 36, 134–139; doi:10.1038/hr.2012.147; published online 4 October 2012
After the publication of this article, the authors noticed an error in Figure 2. The asterisk (*) was missing from the bar labeled ‘Azilsartan’ in the WT receptor group. The correct figure is shown below.
Percent of maximum IP production with or without 1 μM of the ARBs or 0.1 μM [Sar1]Ang II in COS1 cells transiently expressing the WT, N111G, N111G/K199Q or N111G/Q257A AT1 receptor. [Sar1]Ang II or ARB was added to the medium for 10 min. Percentage (%) maximum IP production indicates [Sar1]Ang II-induced IP production (1920 c.p.m.) in WT AT1 receptor-transfected cells (100%) after adjusting for basal IP production (130 c.p.m.) without treatment in mock-treated cells (0%). *P<0.05 vs. no treatment. #P<0.05 vs. candesartan.
The authors would like to apologise for this error.
Additional information
The online version of the original article can be found at 10.1038/hr.2012.147
Rights and permissions
About this article
Cite this article
Miura, Si., Okabe, A., Matsuo, Y. et al. Erratum: Unique binding behavior of the recently approved angiotensin II receptor blocker azilsartan compared with that of candesartan. Hypertens Res 36, 476 (2013). https://doi.org/10.1038/hr.2013.16
Published:
Issue Date:
DOI: https://doi.org/10.1038/hr.2013.16
